Shire files suit Corepharma for infringing Carbatrol patents

By Lisa Kerner

Erie, Pa., May 18 - Shire plc's subsidiary, Shire Laboratories Inc., filed a lawsuit in the U.S. District Court for the District of New Jersey against Corepharma LLC for infringement of Shire Laboratories' U.S. Patent Nos. 5,326,570 and 5,912,013.

Corepharma filed an abbreviated New Drug Application for generic versions of Shire's 100 mg, 200 mg and 300 mg Carbatrol products, seeking Food and Drug Administration approval to market its generic products prior to the expiration of the `570 and `013 patents.

Shire's lawsuit triggers an FDA stay of approval up to 30 months under Hatch-Waxman legislation, according to a company news release.

Shire is a specialty pharmaceutical company based in Basingstoke, U.K., and in Philadelphia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.